Radioactive antibodies: Selective targeting and treatment of cancer and other diseases

Applied Radiology

Volumn 36, Issue 4, 2007, Pages 10-29

  Goldenberg, David M ^a   Sharkey, Robert M ^b   Barbet, Jacques ^c   Chatal, Jean Francois ^d  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b GARDEN STATE CANCER CENTER   (United States)

^c INSERM   (France)

^d CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIVATUZUMAB RE 186; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY I 131; CD20 ANTIBODY; CD20 ANTIGEN; EPRATUZUMAB Y 90; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FUNGUS ANTIBODY; GALLIUM 68; IBRITUMOMAB TIUXETAN; INTERLEUKIN 2 RECEPTOR ANTIBODY Y 90; IODINE 125; IODINE 131; MONOCLONAL ANTIBODY 425 I 125; MONOCLONAL ANTIBODY 8H9 I 131; MONOCLONAL ANTIBODY A33 I 125; MONOCLONAL ANTIBODY A33 I 131; MONOCLONAL ANTIBODY BC 2 Y 90; MONOCLONAL ANTIBODY BC4 Y 90; MONOCLONAL ANTIBODY BC8 I 131; MONOCLONAL ANTIBODY HU3S193 Y 90; MONOCLONAL ANTIBODY HUM195 BI 213; MONOCLONAL ANTIBODY J591 LU 177; MONOCLONAL ANTIBODY PAM4 Y 90; RADIOISOTOPE; RITUXIMAB; TECHNETIUM 99M; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL TUMOR; ACQUIRED IMMUNE DEFICIENCY SYNDROME; APPENDECTOMY; APPENDICITIS; ARTICLE; BRAIN CANCER; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG TARGETING; EMERGENCY CARE; GENE TARGETING; HUMAN; ISOTOPE LABELING; LEUKEMIA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PNEUMOCYSTIS PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOACTIVITY; RADIOIMMUNOTHERAPY; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 34250348709     PISSN: 01609963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (104)

1. Passalaqua AM, Klein RL, Wegener WA, et al. Diagnosing suspected acute nonclassic appendicitis with sulesomab, a radiolabele d antigranulocyte antibody imaging agent. J Pediatr Surg. 2004; 39: 1338-1344.
2. Goldenberg DM, Sharkey RM, Udem S, et al. Immunoscintigraphy of Pneumocystis carinii pneumonia in AIDS patients. J Nucl Med. 1994;35:1028-1034.
3. Chatal JF, Harousseau JL, Griesinger F, et al. Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. J Clin Oncol (Meeting Abstracts). 2004;22:2545.
4. Himmelweit F. The Collected Papers of Paul Ehrlich. Vol 3. London, UK: Pergamon; 1960:59.
5. Pressman D; Korngold L. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer. 1953;6:619-623.
6. Bale WF; Spar IR. Studies directed toward the use of antibodies as carriers of radioactivity for therapy. Adv Biol Med Phys. 1957;5:285-356.
7. Hnatowich DJ, Layne WW, Childs RL, et al. Radioactive labeling of antibody: A simple and efficient method. Science. 1983; 220:613-615.
8. Scheinberg DA, Strand M, Gansow OA. Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science. 1982; 215: 1511-1513.
9. Brechbiel MW, Gansow OA. Backbone-substituted DTPA ligands for 90Y radioimmunotherapy. Bioconjug Chem. 1991;2:187-194.
10. Moi MK, DeNardo SJ, Meares CF. Stable bifunctional chelates of metals used in radiotherapy. Cancer Res. 1990;50(3 suppl):789s-793s.
11. Goldenberg DM, Hansen HJ. Carcinoembryonic antigen present in human colonic neoplasms serially propagated in hamsters. Science. 1972;175:1117-1118.
12. Gold P; Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965;122:467-481.
13. Primus FJ, Wang RH, Goldenberg DM, Hansen HJ. Localization of human GW-39 tumors in hamsters by radiolabeled heterospecific antibody to carcinoembryonic antigen. Cancer Res. 1973;33: 2977-2982.
14. Goldenberg DM, Preston DF, Primus FJ, Hansen HJ. Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G. Cancer Res. 1974;34(1):1-9.
15. Goldenberg DM, DeLand F, Kim E, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med. 1978; 298:1384-1386.
16. Goldenberg DM. Introduction to the International Conference on the Clinical Uses of Carcinoembryonic Antigen. Cancer. 1978;42(3 suppl):1397-1398.
17. Mach JP, Carrel S, Merenda C, et al. In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature. 1974;248:704-706.
18. Mach JP, Carrel S, Fomi M, et al. Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: A critical evaluation. N Engl J Med. 1980;303:5-10.
19. Becker W, Bair J, Behr T, et al. Detection of soft-tissue infections and osteomyelitis using a technetium-99m-labeled anti-granulocyte monoclonal antibody fragment. J Nucl Med. 1994;35:1436-1443.
20. Becker W, Goldenberg DM, Wolf F. The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. Semin Nucl Med. 1994; 24:142-153.
21. Becker W, Palestro CJ, Winship J, et al. Rapid imaging of infections with a monoclonal antibody fragment (LeukoScan). Clin Orthop Relat Res. 1996; (329):263-272.
22. Dadachova E, Nakouszi A, Bryan RA, Casadevall A. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci USA. 2003;100:10942-10947.
23. Dadachova E, Casadevall A. Treatment of infection with radiolabeled antibodies. Q J Nucl Med Mol Imaging. 2006:50:193-204.
24. Moffat FL Jr, Pinsky CM, Hammershaimb L, et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: Results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol. 1996:14:2295-2305.
25. Goldenberg DM, Juweid M, Dunn RM, Sharkey RM. Cancer imaging with radiolabeled antibodies: New advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy. J Nucl Med Technol. 1997;25:18-23.
26. Goldenberg DM. Cancer imaging with CEA antibodies: Historical and current perspectives. Int J Biol Markers. 1992;7:183-188.
27. Abdel-Nabi H, Doerr RJ. Clinical applications of indium-111-labeled monoclonal antibody imaging in colorectal cancer patients. Semin Nucl Med. 1993; 23:99-113.
28. Lamb HM, Faulds D. Capromab pendetide. A review of its use as an imaging agent in prostate cancer. Drugs Aging. 1998;12:293-304.
29. Yao D, Trabulsi EJ, Kostakoglu L, et al. The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol. 2002;20:211-218.
30. Goldenberg DM, DeLand FH. Clinical studies of prostatic cancer imaging with radiolabeled antibodies against prostatic acid phosphatase. Urol Clin North Am. 1984;11:277-281.
31. Murthy S, Sharkey RM, Goldenberg DM, et al. Lymphoma imaging with a new technetium-99m labeled antibody, LL2. Eur J Nucl Med. 1992;19:394-401. Comment in: Eur J Nucl Med. 1992;19:385-386.
32. Dresel S, Kirsch CM, Tatsch K, et al. Detection of hepatocellular carcinoma with a new alpha-fetoprotein antibody imaging kit. J Clin Oncol. 1997; 15:2683-2690.
33. Matsumori A, Yamada T, Tamaki N, et al. Persistent uptake of indium-111-antimyosin monoclonal antibody in patients with myocardial infarction. Am Heart J. 1990;120:1026-1030.
34. Khaw BA, Haber E. Imaging necrotic myocardium: Detection with 99mTc-pyrophosphate and radiolabeled antimyosin. Cardiol Clin. 1989;7: 577-588.
35. Khaw BA, Narula J. Antibody imaging in the evaluation of cardiovascular diseases. J Nucl Cardiol. 1994;1(5 Pt 1):457-476. Erratum in: J Nucl Cardiol. 1994;1:585.
36. Boerman OC, Rennen H, Oyen WJ, Corstens FH. Radiopharmaceuticals to image infection and inflammation. Semin Nucl Med. 2001;31:286-295.
37. Love C, Palestra CJ. Radionuclide imaging of infection. J Nucl Med Technol. 2004;32(2):47-57.
38. Gratz S, Schipper ML, Dorner J, et al. LeukoScan for imaging infection in different clinical settings: A retrospective evaluation and extended review of the literature. Clin Nucl Med. 2003;28: 267-276.
39. Cerqueira MD. Current status of radionuclide tracer imaging of thrombi and atheroma. Semin Nucl Med. 1999;29:339-351.
40. Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Exp Opin Drug Deliv. 2006; 3(1):53-70.
41. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl. 1988; 3:96-101.
42. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1(anti-CD37) antibody. J Clin Oncol. 1989;7:1027-1038.
43. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336-340.
44. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237-1247.
45. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934-2942. Comment in: Blood. 2001; 98:1275-1276.
46. Press OW, Leonard JP, Coiffier B, et al. Immunotherapy of non-Hodgkin's lymphomas. Hematology Am Soc Hematol Educ Program. 2001; 221-240.
47. Gopal AK, Pagel JM, Rajendran JG, et al. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. Biol Blood Marrow Transplant. 2006; 12:697-702.
48. Press OW, Unger JM, Braziel RM, et al for the Southwest Oncology Group. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143-4149.
49. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26(5 suppl 14): 66-73.
50. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20:2453-2463.
51. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996; 2:457-470.
52. Sharkey RM, Burton J, Goldenberg DM. Radioimmunotherapy of non-Hodgkin's lymphoma: A critical appraisal. Expert Rev Clin Immunol. 2005;1:47-62.
53. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001;19:3918-3928.
54. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449. Comment in: N Engl J Med. 2005;352:496-498.
55. Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004;10: 7792-7798.
56. Buchegger F, Antonescu C, Delaloye AB, et al. Long-term complete responses after 131l-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer. 2006;94: 1770-1776.
57. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23: 7565-7573.
58. Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm. 2005;20:185-188.
59. Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005; 105:4576-4582.
60. Dosik AD, Coleman M, Kostakoglu L, et al. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer. 2006;106: 616-622.
61. Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol. 2005;23:7985-7993.
62. Linden O, Hindorf C, Cavallin-Stahl E, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res. 2005; 11:5215-5122.
63. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233-1239.
64. Kotzerke J, Bunjes D, Scheinberg DA. Radio-immunoconjugates in acute leukemia treatment: The future is radiant. Bone Marrow Transplant. 2005; 36:1021-1026.
65. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005;46(suppl 1):115s-127s.
66. Schlom J, Colcher D, Szpak CA, et al. A monoclonal antibody (B72.3) to adenocarcinoma of the colon and related tumors. Prog Clin Biol Res. 1989; 288:63-72.
67. Colcher D, Minelli MF, Roselli M, et al. Radio-immunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res. 1988;48:4597-4603.
68. Goel A, Colcher D, Baranowska-Kortylewicz J, et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: Improved biodistribution and potential for the rapeutic application. Cancer Res. 2000;60:6964-6971.
69. Pavlinkova G, Booth BJ, Batra SK, Colcher D. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. Clin Cancer Res. 1999;5:2613-2919.
70. Sickle-Santanello BJ, O'Dwyer PJ, Mojzisik C, et al. Radioimmunoguided surgery using the monoclonal antibody B72.3 in colorectal tumors. Dis Colon Rectum. 1987;30:761-764.
71. Blumenthal RD, Sharkey RM, Haywood L, et al. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Cancer Res. 1992; 52:6036-6044.
72. Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer. 2002;94 (4 suppl):1373-1381.
73. Liersch T, Meller J, Kulle B, et al. Phase-II trial of CEA radioimmunotherapy with 131I-labetuzumab post salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results. J Clin Oncol. 2005;23:6763-6770.
74. Riva P, Franceschi G, Riva N, et al. Role of nuclear medicine in the treatment of malignant gliomas: The locoregional radioimmunotherapy approach. Eur J Nucl Med. 2000;27:601-609.
75. Riva P, Marangolo M, Lazzari S, et al. Locoregional immunotherapy of human ovarian cancer: Preliminary results. Int J Rad Appl Instrum B. 1989; 16:659-666.
76. Grana C, Bartolomei M, Handkiewicz D, et al. Radioimmunotherapy in advanced ovarian cancer: Is there a role for pre-targeting with 90Y-biotin? Gynecol Oncol. 2004;93:691-698.
77. Grana C, Chinol M, Robertson C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br J Cancer. 2002;86:207-212.
78. Zalutsky MR. Current status of therapy of solid tumors: Brain tumor therapy. J Nucl Med. 2005;46 (suppl 1):151s-156s.
79. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131) I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002; 20:1389-1397.
80. Meredith RF, Alvarez RD, Partridge EE, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biother Radiopharm. 2001;16:305-315.
81. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med. 2005. 46(suppl 1):199s-204s.
82. Mattes MJ. Radionudide-antibody conjugates for single-cell cytotoxicity. Cancer. 2002;94(4 suppl): 1215-1223.
83. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
84. Wu AM. Engineering multivalent antibody fragments for in vivo targeting. Methods Mol Biol. 2004; 248:209-225.
85. Chester KA, Bhatia J, Boxer G, et al. Clinical applications of phage-derived sFvs and sFv fusion proteins. Dis Markers. 2000;16(1-2):53-62.
86. Reardan DT, Meares CF, Goodwin DA, et al. Antibodies against metal chelates. Nature. 1985; 316:265-268.
87. Goodwin DA, Meares CF, McCall MJ, et al. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med. 1988;29:226-234.
88. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294-1302.
89. Paganelli G, Magnani P, Fazio F. Pretargeting of carcinomas with the avidin-biotin system. Int J Biol Markers. 1993;8:155-159.
90. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA. 2000;97:1802-1807.
91. Le Doussal JM, Martin M, Gautherot E, et al. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358-1366.
92. Boerman OC, Kranenborg MH, Oosterwijk E, et al. Pretargeting of renal cell carcinoma: Improved tumor targeting with a bivalent chelate. Cancer Res. 1999;59:4400-4405.
93. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther. 2002; 1:553-563.
94. Rossi EA, Chang C-H, Losman MJ, et al. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res. 2005; 11(19 Pt 2):7122S-7129S.
95. Rossi EA, Goldenberg DM, Cardillo TM, et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA. 2006;103: 6841-6846.
96. Sharkey RM, Cardillo TM, Rossi EA, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nature Med. 2005; 11:1250-1255.
97. McBride WJ, Zanzonico P, Sharkey RM, et al. Bispecific antibody pretargeting PET (ImmunoPET) with an 124I-labeled hapten-peptide. J Nucl Med. 2006;47: 1678-1688.
98. Sharkey RM, Karacay H, Cardillo TM, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res. 2005;11(19 Pt 2):7109s-7121 s.
99. Karacay H, Brard PY, Sharkey RM, et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res. 2005;11: 7879-7885.
100. Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823-834.
101. Kraeber-Bodere F, Rousseau C, Bodet-Milin C, et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med. 2006;47:247-255.
102. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006;24:1705-1711.
103. Karacay H, Sharkey RM, McBride WJ, et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: Role of the bispecific antibody's valency for the tumor target antigen. Bioconjug Chem. 2002;13:1054-1070.
104. Sharkey RM, Karacay H, Chang CH, et al. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia. 2005; 19:1064-1069.